SEC Company Response from LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT, LIXTW) (CIK 0001335105) (NMAD) — May 14, 2007

LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT, LIXTW) (CIK 0001335105)
Date: May 14, 2007 · CIK: 0001335105 · Accession: 0001144204-07-024806

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-137208

Date

May 14, 2007

Author

Chief

Form

CORRESP

Company

LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT, LIXTW) (CIK 0001335105)

Letter

United States Securities and Exchange Commission Office of Emerging Growth Companies Lixte Biotechnology Holdings, Inc. Amendment No. 5 to Form SB-2 Filed May 5, 2007 File No. 333-137208

Dear Mr. Mancuso:

Lixte Biotechnology Holdings, Inc. (the “Company”) hereby represents that there are no material changes in the financial conditions and results of operations from the financial statements as previously reported in Amendment No. 5 to the Registration Statement on Form SB-2.

Very
truly yours,
/s/
John Kovach, M.D.

Show Raw Text

CORRESP
1
filename1.htm

    File
      No. 2392-1

    May
      14,
      2007

    Via
      Fax (202) 772-9218 and Edgar

    Mr. Russell
      Mancuso

    Branch
      Chief

    United
      States Securities and Exchange Commission

    Office
      of
      Emerging Growth Companies

    Mail
      Stop
      3561

    100
      F
      Street, N.E.

    Washington,
      D.C. 20549

              Re:

              Lixte
                Biotechnology Holdings, Inc.

                Amendment
                  No. 5 to Form SB-2

                Filed
                  May 5, 2007

                File
                  No. 333-137208

    Dear
      Mr. Mancuso:

    Lixte
      Biotechnology Holdings, Inc. (the “Company”) hereby represents that there are no
      material changes in the financial conditions and results of operations from
      the
      financial statements as previously reported in Amendment No. 5 to the
      Registration Statement on Form SB-2.

              Very
                truly yours,

              /s/
                John Kovach, M.D.

              Chief
                Executive Officer

            cc:

              David
                Ficksman

    Eduardo
      Aleman

SecProbe.io